ライフサイエンスコーパス: D-penicillamine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 s obtained by modification of the amino acid D-penicillamine.

2 lticenter trial of high-dose versus low-dose D-penicillamine.

3 se MG had recently been provoked by the drug D-penicillamine.

4 2-year time period in patients treated with D-penicillamine.

5 id (3), a cyclized N-protected derivative of D(-)-penicillamine.

6 D-Penicillamine(2,5)-enkephalin (DPDPE) is a potent opio

7 pioid receptor agonists, deltorphin II, and [D-penicillamine(2,5)]-enkephalin.

8 By contrast the delta-opioid ligand [2-D-penicillamine, 5-D-penicillamine]enkephalin (DPDPE) ha

9 lied model was verified by exposing worms to D-penicillamine and menadione.

10 Cysteine differs from the antiarthritis drug D-penicillamine by only two methyl groups on the beta-ca

11 ne of a series of FSDs (N-acetyl-L-cysteine, D-penicillamine, captopril, L-cysteine, or reduced gluta

12 binds tightly to the active site zinc, while D-penicillamine catalyzes metal removal.

13 ase, we treated mice with a copper chelator, D-(-)-penicillamine (D-PEN), starting immediately follow

14 m 3 RCTs examining high-dose versus low-dose D-penicillamine (D-Pen Trial), recombinant human relaxin

15 ticancer therapy with a novel combination of D-penicillamine (D-pen) and Idarubicin (Ida) in a synthe

16 The antiarthritis drug D-penicillamine (D-PEN) catalyzes zinc(II) transfer from

17 ects and subjects previously reported in the D-penicillamine (D-Pen) trial.

18 In contrast, the antiarthritis drug D-penicillamine, D-PEN, which differs from D-Cys only by

19 +)-doped quantum dots (Qdots) decorated with D-penicillamine (DPA-MnQdots).

20 trolled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective.

21 th PBC who had received ineffective therapy (D-penicillamine [DPCA] or placebo) for 5.6 +/- 0.07 year

22 he delta-opioid ligand [2-D-penicillamine, 5-D-penicillamine]enkephalin (DPDPE) had no effect on thes

23 fficacy, whereas the results of therapy with D-penicillamine have been disappointing.

24 articipated in the High-Dose Versus Low-Dose D-Penicillamine in Early Diffuse SSc trial.

25 drug (Thalidomide) and false negative drug (D-penicillamine) in the conventional mouse embryonic ste

26 s and provides insight into the mechanism of D-penicillamine inhibition.

27 ulfasalazine, auranofin, intramuscular gold, D-penicillamine, methotrexate, and/or azathioprine).

28 The effects of other drugs, including D-penicillamine, nonsteroidal antiinflammatory drugs (NS

29 esis of a series of N-terminal dipeptides of D(-)-penicillamine, prepared from the synthon 3-formyl-2

30 D-penicillamine protected against advanced glycation end

31 cles for NO, the NO donor S-nitroso-N-acetyl-D-penicillamine (SNAP) was encapsulated within poly(lact

32 Antecedent D-penicillamine therapy may have been protective against

33 The duration of the use of D-penicillamine was significantly associated with improv

34 Similarly, d-penicillamine, which inhibits lysyl oxidase enzymatic

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。